Working… Menu

1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02000596
Recruitment Status : Terminated (funding withdrawn by sponsor)
First Posted : December 4, 2013
Last Update Posted : February 7, 2018
Genentech, Inc.
Information provided by (Responsible Party):
Katherine Tkaczuk, University of Maryland, College Park

Results Submitted - Not Posted on
Results information has been submitted to by the sponsor or investigator, but is not yet publicly available (or "posted") on The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
Recruitment Status : Terminated
Actual Primary Completion Date : November 2015
Actual Study Completion Date : January 2016
Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 June 11, 2018
July 9, 2018
2 March 22, 2019
April 19, 2019
3 October 18, 2019
November 5, 2019
4 November 5, 2019
November 22, 2019
5 December 10, 2019
December 24, 2019
6 March 13, 2020
March 25, 2020